2.99 USD
+0.07
2.40%
At close Dec 20, 4:00 PM EST
After hours
3.11
+0.12
4.01%
1 day
2.40%
5 days
-18.08%
1 month
11.57%
3 months
-30.79%
6 months
2.40%
Year to date
-18.97%
1 year
-2.29%
5 years
-86.15%
10 years
-86.15%
 

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Employees: 156

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

427% more call options, than puts

Call options by funds: $1.98M | Put options by funds: $376K

67% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 18

32% more capital invested

Capital invested by funds: $209M [Q2] → $277M (+$67.1M) [Q3]

11% more funds holding

Funds holding: 110 [Q2] → 122 (+12) [Q3]

3.61% more ownership

Funds ownership: 60.14% [Q2] → 63.74% (+3.61%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 33

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
134%
upside
Avg. target
$8.50
184%
upside
High target
$10
234%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
30% 1-year accuracy
52 / 173 met price target
134%upside
$7
Buy
Reiterated
13 Dec 2024
Guggenheim
Vamil Divan
40% 1-year accuracy
8 / 20 met price target
234%upside
$10
Buy
Reiterated
3 Dec 2024

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
Absci Corporation (ABSI) Q3 2024 Earnings Call Transcript
Absci Corporation (NASDAQ:ABSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Srikripa Devarakonda – Truist Securities Brendan Smith - TD Cowen George Farmer – Scotiabank Vamil Divan - Guggenheim Securities Operator Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call.
Absci Corporation (ABSI) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
Neutral
GlobeNewsWire
1 month ago
Absci to Host R&D Day on December 12, 2024
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City.
Absci to Host R&D Day on December 12, 2024
Neutral
GlobeNewsWire
2 months ago
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024.
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
Positive
Seeking Alpha
2 months ago
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033.
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Positive
The Motley Fool
3 months ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood bought shares of Tempus AI, Blade Air Mobility, and Absci on Thursday. Tempus AI was a broken IPO shortly after going public two months ago, but it soared 34% in August.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Neutral
GlobeNewsWire
4 months ago
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
Absci to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
4 months ago
Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript
Absci Corporation (NASDAQ:ABSI ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Steven Mah - TD Cowen Srikripa Devarakonda - Truist George Farmer - Scotiabank Scott Schoenhaus - KeyBanc Operator Good day and thank you for standing by. Welcome to the Absci Second Quarter 2024 Business Update Conference Call.
Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript
Negative
Zacks Investment Research
4 months ago
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.27 per share a year ago.
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
Charts implemented using Lightweight Charts™